Reem Karmali

Clinical trials

• Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

  Principal investigator · Recruiting · Phase 2

  Reem Karmali

  2025–2029
• Pembrolizumab and Tazemetostat to Overcome Immune Tolerance Following ASCT or CAR T-cell Therapy in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

  Principal investigator · Active not recruiting · Phase 2

  Northwestern University

  2024–2028
• Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma

  Principal investigator · Active not recruiting · Phase 2

  Northwestern University

  2022–2029
• Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma

  Principal investigator · Completed · Phase 1

  Northwestern University

  2019–2024